ISPOR 13th European Congress Released Presentations
 

RELEASED PRESENTATIONS


PLENARY SESSIONS
 
FIRST PLENARY SESSION:
IMPROVING THE EFFICIENCY IN ASSESSMENT OF HEALTH TECHNOLOGY IN EUROPE
 
Assessment of Health Technology in Europe: Taking Stock of the Inefficiencies
Bengt Jonsson PhD
Professor of Health Economics, Centre for Health Economics, Stockholm School of Economics, Stockholm, Sweden
 
The European network for HTA (EUnetHTA) Joint Action Strategy & Core Model
Finn Børlum Kristensen MD, PhD
Director of Coordinating Secretariat, European network for Health Technology Assessment (EUnetHTA) and Chairman of the EUnetHTA Executive Committee, Copenhagen, Denmark
 
Relative Effectiveness Assessment of Pharmaceuticals: A EUnetHTA Joint Action Initiative
Wim Goettsch PhD
Deputy Secretary of the Medicinal Products Reimbursement Committee, Health Care Insurance Board (CVZ) and European network for Health Technology Assessment (EUnetHTA) Partner, Diemen, The Netherlands
 
A Stakeholder Perspective on HTA Inefficiencies in Europe and the HTA Joint Action Initiative
Clare McGrath
Senior Director, HTA Policy, Europe, Pfizer Ltd., Tadworth, Surrey, UK

SECOND PLENARY SESSION:
HEALTH TECHNOLOGY ASSESSMENT (HTA) AND DECISION-MAKING IN EUROPE: BALANCING HEALTH CARE BUDGETS AND ACCESS TO INNOVATION
 
HEALTH TECHNOLOGY ASSESSMENT (HTA) AND DECISION-MAKING IN EUROPE: BALANCING HEALTH CARE BUDGETS AND ACCESS TO INNOVATION
Jan Švihovec MD, PhD, DrSc
Professor, Head of Department of Pharmacology, 2nd Medical Faculty, Charles University, Prague, Czech Republic
 

Key Trends and Developments in Health Technology Decision-Making in Europe
Michael Drummond MCom, DPhil
Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK

 
Health Technology Assessment and Decision-making in Europe: An Industry Perspective
Ansgar Hebborn PhD
Head – Global Payer & HTA Program Policy, F. Hoffmann-La Roche AG, Basel, Switzerland
 
Making Innovative Drugs Accessible In The European Union: Recommendations from the Belgian EU Presidency
Lieven Annemans PhD, MSc
Professor, Centre for Health Economics Research and Health Economist, I-CHER, University of Ghent, Ghent, Belgium

THIRD PLENARY SESSION:
ASSESSING A TECHNOLOGY WITH LIMITED RESOURCES: BUILDING CAPACITY WITHOUT BREAKING THE BANK
 
Health Technology Assessment with Limited Resources Now and Future Trends in Central and Eastern Europe
Tomáš Doležal, MD, PhD
Director, Institute for Health Economics and Technology Assessment (IHETA), Prague, Czech Republic
 
Evaluating Health Care Technologies with Limited Resources: Lessons Learned from Austria
Elisabeth Breyer MMag
Federal Institute for Quality in Health Care (BIQG), Health Austria GmbH, Vienna, Austria
 
Evaluating Health Care Technologies with Limited Resources: Lessons Learned from Scotland
Kenneth R. Paterson MBChB, FRCP, FFPM
Chair, Scottish Medicines Consortium and Consultant Physician, Glasgow Royal Infirmary, Glasgow, UK
 
Evaluating Healthcare Technologies with Limited Resources: Lessons Learned from Poland
Iga Lipska MD
Director of Health Technology Assessment, Agency for Health Technology Assessment in Poland (AHTAPol), Warsaw, Poland

PODIUM AND POSTER PRESENTATIONS
 

For contributed research podium and poster abstracts and released slide or poster presentations for the ISPOR 13th Annual European Congress, see: ISPOR Outcomes Research Digest an electronic database of over 16,000 research papers presented at ISPOR Annual International Meetings, ISPOR Annual European Congresses, and biennial ISPOR Asia-Pacific & Latin America Conferences from 1998 to date.

  • ISPOR Outcomes Research Digest:  http://www.ispor.org/research_study_digest/research_index.asp
  • Under Meeting select 13th Annual European Congress – Prague, Czech Republic - 2010
  • Select Search for all research podium and poster abstracts and available slide or poster presentations from the meeting. Alternatively search by disease/disorder, topic or subtopic.

 WORKSHOP PRESENTATIONS
 
W1: CONDUCTING & INTERPRETING INDIRECT TREATMENT COMPARISON AND NETWORK META-ANALYSIS: LEARNING THE BASICS
Discussion Leaders: Jeroen P. Jansen PhD, MSc, Research Director, Mapi Values, Boston, MA, USA; Neil Hawkins PhD, Director, Oxford Outcomes Ltd, Oxford, UK; Joseph C. Cappelleri PhD, MPH, Pfizer Inc, New London, CT, USA; Rachael Fleurence PhD, Senior Research Scientist and Director, Practice for Evidence Review and Synthesis, United BioSource Corporation, Bethesda, MD, USA

ISSUE PANEL PRESENTATIONS

IP1:  ARE DIAGNOSTICS AND PERSONALIZED MEDICINE IN FLUX?  IMPLICATIONS OF GLOBAL POLICY CHANGES FOR HEALTH ECONOMICS AND OUTCOMES RESEARCH

OVERVIEW OF KEY POLICY DOMAINS & ISSUES RELATED TO DIAGNOSTICS AND PERSONALIZED MEDICINE SCENARIOS
Eric Faulkner MPH, Senior Director, RTI Health Solutions, Research Triangle Park, NC, USA

REIMBURSEMENT OF DIAGNOSTICS AS A KEY FACTOR FOR THE DELIVERY OF INNOVATIVE TREATMENTS FOR THE RIGHT PATIENTS, AT THE RIGHT TIME AND RIGHT DOSE
Diego Ossa, MD, Head of Health Economics, Molecular Diagnostics, Novartis Pharma, AG, Basel, Switzerland


IP2:  METHODS OR PRAGMATISM:  WHO SHOULD HAVE THE SAY IN HEALTH ECONOMIC ASSESSMENT?

METHODS OR PRAGMATISM:  WHO SHOULD HAVE THE SAY IN HEALTH ECONOMIC ASSESSMENT?
Jaime Caro, MDCM FRCPC FACP, Senior Vice President of Health Economics, United BioSource Corporation, Lexington, MA, USA

Methods or Pragmatism:  Who should have the Say in Health Economic Assessment?  Germany‘s Approach
Andreas Gerber, MD, PhD, Head, Department of Health Economics, Institute for Quality and Efficiency in Health Care (IQWIG), Cologne, Germany

Methods or pragmatism: Who should have the say in health economic assessment?
Lise Rochaix, PhD, Professor, Commission d’evaluation economique et de santé publique (CEESP), Haute Autorite de Sante, Saint-Denis La Plaine, France

Methods or Pragmatism:  RCT or real life data?  The Dutch Approach
Gert Jan van der Wilt, PhD, Professor, Department of Epidemiology, Biostatistics and HTA, Radboud University Medical Centre, Nijmegen, The Netherlands


IP3:  THE VALUE OF QALY:  IS THERE A SINGLE THRESHOLD VALUE OR DOES CONTEXT MATTER?

There is no single value of a QALY – context matters - in terms of the level of decision making!
Sandra Erntoft, PhD, Project Manager, The Swedish Institute for Health Economics (IHE), Lund, Sweden


IP4:  RARE (ORPHAN) DISEASE:  TENSION BETWEEN GOVERNMENT SUPPORT OF DEVELOPING NEW THERAPIES AND REIMBURSEMENT PROCESSES?  PERSPECTIVES FROM EU-5 (GERMANY, UK, FRANCE, SPAIN AND ITALY), CENTRAL AND EASTERN EUROPE, USA AND CANADA

Orphan Diseases - Tension Between Government Support for Developing New Therapies and Reimbursement Processes:  Perspectives From North America
Chris Pashos, PhD, Vice President, United BioSource Corporation, Lexington, MA, USA


IP5:  IS ANY DATA BETTER THAN NO DATA?  THE USE OF MIXED MODALITIES FOR PRO DATA COLLECTION IN CLINICAL TRIALS

IS ANY DATA BETTER THAN NO DATA?  THE USE OF MIXED METHODS & MODES FOR PRO DATA COLLECTION IN CLINICAL TRIALS
Sonya Eremenco, MA, e-PRO Manager, United BioSource Corporation, Bethesda, MD, USA

Mixing Methods and/or Modes of PRO Data Collection in Clinical Trials:  Issues to Consider
Stephen Joel Coons, PhD, Director, Patient-Reported Outcomes (PRO) Consortium, Critical Path Institute, Tucson, AZ, USA

Potential Benefits of Mixing Methods or Modes in Clinical Research
Antonia Bennett, PhD, Investigator, Health Outcomes Group, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Is any data better than no data?  Use of mixed methods and modes for PRO data collection in clinical trials: An industry perspective
Tara Symonds, PhD, Senior Director, PRO Centre of Excellence, Global Market Access, PCBU, Pfizer Ltd., Sandwich, Kent, UK


IP6:  UTILITY MEASUREMENT CHALLENGES IN CHILD HEALTH ECONOMIC EVALUATION:  WHAT METHOD TO USE?

Utility Measurement Challenges in Child Health Economic Evaluation: What Method to Use?
Andreas Gerber, MD, PhD, Head, Department of Health Economics, Institute for Quality and Efficiency in Health Care (IQWiG), Cologne, Germany


IP7:  THE COST-EFFECTIVENESS THRESHOLD:  HOW SHOULD WE GET RELIABLE EMPIRICAL ESTIMATES?

The Cost-Effectiveness Threshold: How Should We Get Reliable Empirical Estimates?
Mark J. Sculpher, PhD, Professor of Health Economics, Centre for Health Economics, The University of York, Heslington, York, UK

The cost-effectiveness threshold:  what it is, what its not and how to estimate it?
Karl Claxton, PhD, Professor of Health Economics, Centre for Health Economics, The University of York, Heslington, York, UK


IP8:  RELATIVE EFFICACY AND RELATIVE EFFECTIVENESS:  DO REGULATORY AGENCIES AND REIMBURSEMENT AGENCIES HAVE THE SAME NEEDS?

RELATIVE EFFICACY AND RELATIVE EFFECTIVENESS:  DO REGULATORY AGENCIES AND REIMBURSEMENT AGENCIES HAVE THE SAME NEEDS?
Wim Goettsch, PhD, Deputy Secretary of the  Medicinal Products Reimbursement Committee, Health Care Insurance Board (CVZ), and European network for Health Technology Assessment (EUnetHTA) Partner, Diemen, The Netherlands

RELATIVE EFFICACY AND RELATIVE EFFECTIVENESS:  DO REGULATORY AGENCIES AND REIMBURSEMENT AGENCIES HAVE THE SAME NEEDS?
Elisabeth George, PhD, Associate Director, Appraisals and European network Health Technology Assessment (EUnetHTA) Partner, National Institute for Health and Clinical Excellence, London, UK

Regulators and HTA: do we have the same need?
Eric Abadie, PhD, President du CHMP, EMEA, Conseiller Scientifique Aupres du Directeur General, Direction Generale, Saint Denis, France

RELATIVE EFFICACY AND RELATIVE EFFECTIVENESS:  DO REGULATORY AGENCIES AND REIMBURSEMENT AGENCIES HAVE THE SAME NEEDS?
Andrea Rappagliosi, MBA, Co-Chair of EFPIA HTA Task Force & Vice President, European Government Affairs and Head of Brussels Office, GlaxoSmithKline, Brussels, Belgium


IP9:  GREECE’S NATIONAL DRUG BUDGET CUT:  WHAT WILL BE ITS IMPACT ON EUROPE?

GREECE’S NATIONAL DRUG BUDGET CUT:  WHAT WILL BE ITS IMPACT ON EUROPE?
John Yfantopoulos, PhD, Professor, Faculty of Political Science and Public Administration, National and Kapodistrian University of Athens, Athens, Greece

GREECE’S NATIONAL DRUG BUDGET CUT:  WHAT WILL BE ITS IMPACT ON EUROPE?  The impact of cost-containments measures on controlling health expenditure
Mary Geitona, PhD, Assistant Professor of Health Economics, Department of Social Policy, University of Peloponnese, Korinth, Greece

GREECE’S NATIONAL DRUG BUDGET CUT:  WHAT WILL BE ITS IMPACT ON EUROPE?
Adam Barak, PhD, Senior Research Scientist, United BioSource Corporation, London, UK

GREECE’S NATIONAL DRUG BUDGET CUT:  WHAT WILL BE ITS IMPACT ON EUROPE?
Konstantinos Frouzis, Vice President, Novartis Hellas; General Secretary SFEE (Pharma Industry Assoc.)


IP10:  HOW MUCH INFORMATION DO WE NEED?  THE ADDED VALUE OF HRQOL AND GENETICS NEXT TO CLINICAL DATA IN CANCER MANAGEMENT

The potential value of genetic data in quality of life research in oncology
Francesca Martinelli, Quality of Life Department, European Organisation for Research and Treatment of Cancer, EORTC Headquarters, Brussels, Belgium


IP12:  REIMBURSEMENT ISSUES IN CANCER DRUGS:  DO WE HAVE TO PAY FOR ALL CANCER DRUGS?

REIMBURSEMENT ISSUES IN CANCER DRUGS:  DO WE HAVE TO PAY FOR ALL CANCER DRUGS?
F. Cankat Tulunay, MD, PhD, Professor, Department of Clinical Pharmacology, Medical School of Ankara University, Ankara, Turkey

REIMBURSEMENT ISSUES IN CANCER DRUGS:  DO WE HAVE TO PAY FOR ALL CANCER DRUGS?
Alan Haycox, PhD, MA, Reader in Health Economics, University of Liverpool Management School, Liverpool, UK

REIMBURSEMENT ISSUES IN CANCER DRUGS:  DO WE HAVE TO PAY FOR ALL CANCER DRUGS?
Kenneth R. Paterson, MBChB, FRCP, FFPM, Chair, Scottish Medicines Consortium and Consultant Physician, Glasgow Royal Infirmary, Glasgow, UK

REIMBURSEMENT ISSUES IN CANCER DRUGS:  DO WE HAVE TO PAY FOR ALL CANCER DRUGS?
Brian Godman, Laboratory of Regulatory Policies, Mario Negri Institute, Milan, Italy, Division of Clinical Pharmacology, Karolinska Institute, Huddinge Hospital, Stockholm, Sweden and University of Liverpool Management School, Liverpool, UK


IP13:  EBM, HTA, CER:  CLEARING THE CONFUSION OR ARE WE NOW CONFUSED AT A HIGHER LEVEL?

EBM, HTA AND CER:  CLEARING THE CONFUSION
Bryan R. Luce, PhD, MBA, Senior Vice President, Science Policy, United BioSource Corporation, Bethesda, MD, USA

EBM, HTA, CER:  What do these mean to the Pharmaceutical Industry?
Marc L. Berger, MD, Vice President, Global Health Outcomes, Eli Lilly and Company, Indianapolis, IN, USA

EBM, HTA AND CER:  CLEARING THE CONFUSION
Penny Mohr, MA, Vice President, Center for Medical Technology Policy, Baltimore, MD, USA

EBM, HTA, CER:  CLEARING THE CONFUSION OR ARE WE NOW CONFUSED AT A HIGHER LEVEL?
Finn Borlum Kristensen, MD, PhD, Director of Coordinating Secretariat, European network for Health Technology Assessment (EUnetHTA) and Chairman of the EUnetHTA Executive Committee, Copenhagen, Denmark


IP14:  QALY OR THE NEED FOR A NEW APPROACH?

QALY OR THE NEED FOR A NEW APPROACH?
J. Jaime Caro, MD, Senior Vice President of Health Economics, United BioSource Corporation, Lexington, MA, USA

QALY OR THE NEED FOR A NEW APPROACH?
Mark J. Sculpher, PhD, Professor of Health Economics, Centre for Health Economics, The University of York, Heslington, York, UK


IP15:  DOES USING HTA IN REIMBURSEMENT DISCOURAGE IMPLEMENTATION OF EU TRANSPARENCY DIRECTIVE?  A RELEVANT EXPERIENCE FROM CENTRAL EASTERN EUROPEAN COUNTRIES

DOES USING HTA IN REIMBURSEMENT DISCOURAGE IMPLEMENTATION OF EU TRANSPARENCY DIRECTIVE?  A RELEVANT EXPERIENCE FROM CENTRAL EASTERN EUROPEAN COUNTRIES
Katarzyna Kolasa, PhD, Senior Research Fellow, Pharmacoeconomics, Warsaw Medical University, Warsaw, Poland


IP16:  CAN WE USE OBSERVATIONAL DATA TO ASSESS THE COST-EFFECTIVENESS OF NEWLY MARKETED DRUGS?

Comparative Effectiveness Research of Newly Marketed Drugs; Methodological Challenges
Sebastian Schneeweiss, MD, ScD, Associate Professor of Medicine and Epidemiology, Vice Chief, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

Assessing the value of newly marketed drugs: the policy issues and the methodological problem
Karl Claxton, PhD, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK

Can we Use Observational Data to Assess the Cost Effectiveness of Newly Marketed Drugs?
Jens Grueger, PhD, Vice President, Head Global Market Access Primary Care, Pfizer Ltd., Tadworth, Surrey, UK


IP17:  HTA LEVEL OF INFLUENCE:  TO WHAT EXTENT DO HTAS INFLUENCE MARKET ACCESS DECISIONS ACROSS GEOGRAPHIES

HTA LEVEL OF INFLUENCE:  TO WHAT EXTENT DO HTAS INFLUENCE MARKET ACCESS DECISIONS ACROSS GEOGRAPHIES
Keiron Sparrowhawk, MBA, MSc, Partner, PriceSpective LLC, London, UK

EUnetHTA | European network for Health Technology Assessment
Finn Borlum Kristensen, MD, PhD, Director of Coordinating Secretariat, European network for Health Technology Assessment (EUnetHTA) and Chairman of the EUnetHTA Executive Committee, Copenhagen, Denmark

Health Technology Assessment in the Czech Republic
Daniel Hodyc, PhD, Partner, ADVANCE Healthcare Management Institute, Prague, Czech Republic


IP18:  WHAT OPPORTUNITIES ARE EMERGING TODAY TO HARMONISE EFFORTS TO GENERATE EVIDENCE NEEDED BY REGULATORS, PAYERS AND DRUG DEVELOPERS?

WHAT OPPORTUNITIES ARE EMERGING TODAY TO HARMONISE EFFORTS TO GENERATE EVIDENCE NEEDED BY REGULATORS, PAYERS AND DRUG DEVELOPERS?
Lisbet Coulton, Director, International Pricing and Reimbursement, United BioSource Corporation – Europe, London, UK

Harmonising the evidence requirements of regulators, payers, drug developers
Hans-Georg Eichler, Senior Medical Officer, European Medicines Agency, London, UK

Opportunities to harmonise efforts to generate evidence needed by regulators, payers and drug developers
Carole Longson, PhD, Director, Centre for Health Technology Evaluation, National Institute for Health and Clinical Excellence, Manchester, UK

What opportunities are emerging today to harmonize efforts to generate evidence needed by regulators, payers and drug developers?
Lise Rochaix, PhD, Professor, Commission d’evaluation economique et de santé publique (SEESP), Haute Autorite de Sante, Saint-Denis La Plaine, France


ISPOR FORUMS
 

ISPOR-SMDM Joint Modeling Good Research Practices Task Force
Modeling Good Research Practices (The Good, The Bad, and The Ambiguous)

ISPOR Prospective Observational Clinical Studies Good Research Practices Task Force
ISPOR GOOD RESEARCH PRACTICES TASK-FORCE ON PROSPECTIVE OBSERVATIONAL CLINICAL STUDIES: WHEN SEEING IS BELIEVING

ISPOR Regional Chapters of Poland, Hungary, Serbia & Greece
HTA: LINKING TODAY’S DECISIONS WITH TOMORROW’S POSSIBILITIES: A PERSPECTIVE FROM POLAND, HUNGARY, GREECE AND SERBIA

ISPOR Regional Chapters of Bosnia-Herzegovina, Croatia, Serbia & Greece
HTA GUIDELINES IN CENTRAL AND EASTERN EUROPE (CEE): DEVELOPMENT, IMPLEMENTATION AND POLICY IMPLICATIONS

ISPOR Regional Chapters of the Czech Republic, Slovakia, Croatia & Turkey
BENEFITS AND BARRIERS OF HTA/PHARMACOECONOMICS IMPLEMENTATION IN THE DECSION-MAKING PROCESS

ISPOR Risk Benefit Management Special Interest Group
COMPARISONS OF FDA AND EMA RISK MANAGEMENT REQUIREMENTS FOR RECENTLY APPROVED PRODUCTS


EDUCATIONAL SYMPOSIA
 

CAPITALISING ON HTA
(Sponsored by Cardiff Research Consortium)

TOOLS AND METHODS FOR CROSS-BORDER COLLABORATION IN HTA
(Co-sponsored by ISPOR and EUnetHTA)

COPING WITH CHAOS: How can health economists deal with a multiplicity of payer perspectives?
(Sponsored by Medaxial)

A Lack of Local Effectiveness, Cost and Epidemiologic Data:  What are the Options for Conducting Pharmacoeconomic Studies in Central and Eastern Europe?
(Sponsored by Pfizer)

APPLYING HTA ACROSS HEALTH CARE SYSTEMS
(Sponsored by European Federation of Pharmaceutical Industries and Associations - EFPIA)

ORPHAN DRUGS IN EUROPE: FUNDING CHALLENGES FOR PAYERS AND DEVELOPERS
(Sponsored by United BioSource Corporation)



13th Annual European Congress Main Page